Download PDF
Dtsch Med Wochenschr 2016; 141(11): 768-771
DOI: 10.1055/s-0042-107202
Klinischer Fortschritt
Hämatologie und Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie des metastasierten malignen Melanoms

Treatment of metastatic malignant melanoma
Monika Schmid-Wendtner
1   Interdisziplinäres Onkologisches Zentrum München (IOZM)
2   Ludwig-Maximilians-Universität München
,
Clemens-Martin Wendtner
3   Klinikum Schwabing, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität München, Klinik für Hämatologie, Onkologie, Immunologie, Palliativmedizin, Infektiologie und Tropenmedizin, München
› Author Affiliations
Further Information

Publication History

Publication Date:
02 June 2016 (online)

Also available at
    Permissions and Reprints

Corrected by:

Therapie des metastasierten malignen MelanomsDtsch Med Wochenschr 2016; 141(14): 1000-1000
DOI: 10.1055/s-0042-111018

Schlüsselwörter

malignes Melanom - Ipilimumab - BRAF-Inhibitoren - MEK-Inhibitoren - PD-1-Inhibitoren

Keywords

malignant melanoma - ipilimumab - BRAF inhibitors - MEK inhibitors - PD-1 inhibitors
 

  • Literatur

  • 1 Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure. Eur J Cancer 2005; 41: 45-60
    CrossrefPubMedGoogle Scholar
  • 2 Balch CM, Gerschenwald JE, Soong SJ et al. Final Version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 2009; 27: 6199-6206
    CrossrefPubMedGoogle Scholar
  • 3 Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516
    CrossrefPubMedGoogle Scholar
  • 4 Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365
    CrossrefPubMedGoogle Scholar
  • 5 Chapman PB, Hauschild A, Robert C et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival – results of the BRIM-3 study. Pigment Cell Melanoma Res 2015; 28: 753-826
    CrossrefPubMedGoogle Scholar
  • 6 Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Eng J Med 2014; 371: 1867-1876
    CrossrefPubMedGoogle Scholar
  • 7 Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888
    CrossrefPubMedGoogle Scholar
  • 8 Hodi JS, O’Day SJ, McDermott DR et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-712
    CrossrefPubMedGoogle Scholar
  • 9 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330
    CrossrefPubMedGoogle Scholar
  • 10 Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532
    CrossrefPubMedGoogle Scholar
  • 11 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017
    CrossrefPubMedGoogle Scholar
  • 12 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34
    CrossrefPubMedGoogle Scholar